Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice

Journal of Nanobiotechnology

Volumn 8, Issue , 2010, Pages

  BarathManiKanth, Selvaraj ^a   Kalishwaralal, Kalimuthu ^a   Sriram, Muthuirulappan ^a   Pandian, SureshBabu R K ^a   Youn, Hyung seop ^b   Eom, SooHyun ^b   Gurunathan, Sangiliyandi ^a  

^a KALASALINGAM UNIVERSITY   (India)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-OXIDANTS; BIODISTRIBUTIONS; BIOLOGICAL ANTIOXIDANT; BLOOD GLUCOSE; BLOOD GLUCOSE LEVEL; DEFENSE ENZYME; DIABETIC MICE; GOLD NANOPARTICLE; GOLD NANOPARTICLES; LIPID PEROXIDATION; ORGAN FUNCTIONS; OXIDATIVE AGENTS; PROTECTIVE EFFECTS; STREPTOZOTOCIN;

BLOOD; CATALYSTS; ENZYME INHIBITION; ENZYMES; FREE RADICAL REACTIONS; FREE RADICALS; GLUCOSE; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; NANOPARTICLES; OXIDANTS; OXIDATIVE STRESS;

GOLD;

CATALASE; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GOLD NANOPARTICLE; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BIOCHEMISTRY; CONTROLLED STUDY; DRUG DISTRIBUTION; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HISTOPATHOLOGY; HYPERGLYCEMIA; LIPID PEROXIDATION; MOUSE; NONHUMAN; STREPTOZOCIN DIABETES;

MUS;

EID: 77954496051     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-8-16     Document Type: Article

References (68)

1. Aylward GW. Progressive changes in diabetics and their management. Eye 2005, 19(10):1115-1118. 10.1038/sj.eye.6701969, 16304592.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004, 27:1047-1053. 10.2337/diacare.27.5.1047, 15111519.
3. Aronson D. Hyperglycemia and pathobiology of diabetic complications. Adv Cardiol 2008, 45:1-16. full_text, 18230953.
4. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91(3A):7A-11A. 10.1016/S0002-9149(02)03144-2, 12645638.
5. Dash D, Shrivastava S. Applying Nanotechnology to Human Health: Revolution in Biomedical Sciences. J Nanotechnology doi: 10.1155/2009/184702.
6. Norton S. A brief history of potable gold. Mol Interv 2008, 8(3):120-125. 10.1124/mi.8.3.1, 18693188.
7. Jeon KI, Byun MS, Jue DM. Gold compound auranofin inhibits Ikappa B kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 2003, 35:61-66.
8. Kim NH, Lee MY, Park SJ, Choi JS, Oh MK, Kim IS. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 2007, 122:607-614. 10.1111/j.1365-2567.2007.02679.x, 2266044, 17645497.
9. Shah ZA, Vohora SB. Antioxidant/Restorative Effects of Calcined Gold Preparations Used in Indian Systems of Medicine against Global and Focal Models of Ischaemia. Pharmacol Toxicol 2002, 90:254-259. 10.1034/j.1600-0773.2002.900505.x, 12076306.
10. Kalishwaralal K, Deepak V, Pandian SRK, Gurunathan S. Biological synthesis of gold nanocubes using Bacillus licheniformis. Bioresour Technol 2009, 100:5356-5358. 10.1016/j.biortech.2009.05.051, 19574037.
11. Guo R, Song Y, Wang G, Murray RW. Does core size matter in the kinetics of ligand exchanges of monolayer-protected Au clusters?. J Am Chem Soc 2005, 127:2752-2757. 10.1021/ja044638c, 15725033.
12. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005, 11:3530-3534. 10.1158/1078-0432.CCR-04-2482, 15867256.
13. Marquis BJ, Love SA, Braun KL, Haynes CL. Analytical methods to assess nanoparticle toxicity. Analyst 2009, 134:425-439. 10.1039/b818082b, 19238274.
14. Reeves CL, Romero DG, Barria MA, Olmedo I, Clos A, Ramanujam VMS, Urayama A, Vergara L, Kogan MJ, Soto C. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochemical and Biophysical Research Communications 2010, 393:649-655. 10.1016/j.bbrc.2010.02.046, 20153731.
15. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles agents: considerations and caveats. Nanomedicine 2008, 3:703-717. 10.2217/17435889.3.5.703, 18817471.
16. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008, 13:248-260. 10.1634/theoncologist.2007-0180, 18378535.
17. Ruggiero D, Lecomte M, Michoud E, Lagarde M, Wiernsperger N. Involvement of cell-cell interactions in the pathogenesis of diabetic retinopathy. Diabetes Metab 1997, 23:30-42.
18. McDonagh PF, Hokama JY. Microvascular perfusion and transport in the diabetic heart. Microcirculation 2000, 7:163-181.
19. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000, 43:957-973. 10.1007/s001250051477, 10990072.
20. Kowluru RA, Kennedy A. Therapeutic potential of anti-oxidants and diabetic retinopathy. Expert Opin Investig Drugs 2001, 10:1665-1676. 10.1517/13543784.10.9.1665, 11772276.
21. Chang TI, Horal M, Jain S, Wang F, Patel R, Loeken MR. Oxidant regulation of gene expression and neural tube development: Insights gained from diabetic pregnancy on molecular causes of neural tube defects. Diabetologia 2003, 46:538-545. 10.1007/s00125-003-1171-z, 12739027.
22. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S. l:Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 2005, 11:3530-3534. 10.1158/1078-0432.CCR-04-2482, 15867256.
23. Kalishwaralal K, Deepak V, Pandian SRK, Gurunathan S. Biological synthesis of gold nanocubes using Bacillus licheniformis. Bioresour Technol 2009, 100:5356-5358. 10.1016/j.biortech.2009.05.051, 19574037.
24. Sheikpranbabu S, Kalishwaralal K, Venkatraman D, Eom SH, Park J, Gurunathan S. Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells. J Nanobiotechnology 2009, 7:8. 10.1186/1477-3155-7-8, 2776000, 19878566.
25. Coonoor EE, Mwakmuka J, Gole A. Gold nanoparticles are taken up by human cells but do not cause acute toxicity. Small 2005, 1:325-327. 10.1002/smll.200400093, 17193451.
26. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, Katayama Y, Niidome Y. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006, 114(3):343-347. 10.1016/j.jconrel.2006.06.017, 16876898.
27. Chen YS, Ching Y, Liau HI, Huang GS. Assessment of the In Vivo Toxicity of Gold Nanoparticles. Nanoscale Res Lett 2009, 4:858-864. 10.1007/s11671-009-9334-6, 2894102, 20596373.
28. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol 2006, 79:248-53. 10.1259/bjr/13169882, 16498039.
29. Singha SJ, Bhattacharya H, Datta AK, Dasgupta. Anti-glycation activity of gold nanoparticles. Nanomedicine: NBM 2009, 5:21-29.
30. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996, 27(3):567-74. 10.1016/0735-1097(95)00522-6, 8606266.
31. Popper H. Cholestasis. Annu Rev Med 1968, 19:39-56. 10.1146/annurev.me.19.020168.000351, 4871695.
32. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004, 49:309-15.
33. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol 2004, 122:333-338.
34. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19:257-267. 10.2337/diacare.19.3.257, 8742574.
35. Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clin Neurosci 1997, 4:365-370.
36. Ruggiero D, Lecomte M, Michoud E, Lagarde M, Wiernsperger N. Involvement of cell-cell interactions in the pathogenesis of diabetic retinopathy. Diabetes Metab 1997, 23:30-42.
37. Yakimovich NO, Ezhevskii AA, Guseinov DV, Smirnova LA, Gracheva TA, Klychkov KS. Antioxidant properties of gold nanoparticles studied by ESR spectroscopy. Russian Chemical Bulletin 2008, 57(3):520-523.
38. Junpingchen S, Patil S, James F, Mcginnis. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat. Nanotechnol 2006, 1(2):142-50. 10.1038/nnano.2006.91, 18654167.
39. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the Cellular Compartment: A Microscopic Overview. Langmuir 2005, 21(23):10644-10654. 10.1021/la0513712, 16262332.
40. Onizawa S, Aoshiba K, Kajita M, Miyamoto Y, Nagai A. Platinum nanoparticle antioxidants inhibit pulmonary inflammation in mice exposed to cigarette smoke. Pulm Pharmacol Ther 2009, 22:340-9. 10.1016/j.pupt.2008.12.015, 19166956.
41. Wang H, Wei W, Zhang SY, Shen YX, Yue L, Wang NP, Xu SY. Melatonin-selenium nanoparticles inhibit oxidative stress and protect against hepatic injury induced by Bacillus Calmette-Guérin/lipopolysaccharide in mice. J Pineal Res 2005, 39:156-63. 10.1111/j.1600-079X.2005.00215.x, 16098093.
42. Ceriello A. New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy. Diabetes care 2003, 26:1589-1596. 10.2337/diacare.26.5.1589, 12716823.
43. Scampicchio M, Wang J, Blasco AJ, Arribas AS, Mannino S, Escarpa A. Nanoparticle-Based Assays of Antioxidant Activity. Anal Chem 2006, 78:2060-2063. 10.1021/ac052007a, 16536447.
44. Svedberg EB, Ahner J, Shukla N, Ehrman SH, Schilling K. FePt nanoparticle hydrodynamic size and densities from the polyol process as determined by analytical ultracentrifugation. Nanotechnology 2005, 16:953-956.
45. Moghimi SM. Exploiting Bone-Marrow Microvascular Structure for Drug-Delivery and Future Therapies. Adv Drug Deliv Rev 1995, 17:61-73.
46. Moghimi SM, Hunter AC. Capture of stealth nanoparticles by the body's defences. Crit Rev Ther Drug Carrier Syst 2001, 18:527-550.
47. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nature Biotechnol 2007, 25:1165-1170.
48. Banerjee T, Mitra S, Singh AK, Sharma RK, Maitra A. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002, 243:93-105. 10.1016/S0378-5173(02)00267-3, 12176298.
49. Svedberg EB, Ahner J, Shukla N, Ehrman SH, Schilling K. FePt nanoparticle hydrodynamic size and densities from the polyol process as determined by analytical ultracentrifugation. Nanotechnology 2005, 16:953-956.
50. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol 2004, 122:333-338.
51. Nishikawa T, Edelstein D, Du XL, Yamagishi SI, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790. 10.1038/35008121, 10783895.
52. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura, M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High Glucose Level and Free Fatty Acid Stimulate Reactive Oxygen Species Production Through Protein Kinase C-Dependent Activation of NAD(P)H Oxidase in Cultured Vascular Cells. Diabetes 2000, 49:1939-1945. 10.2337/diabetes.49.11.1939, 11078463.
53. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23(5):599-622. 10.1210/er.2001-0039, 12372842.
54. Lao F, Chen L, Li W, Ge C, Qu Y, Sun Q, Zhao Y, Han D, Chen C. Fullerene nanoparticles selectively enter oxidation-damaged cerebral microvessel endothelial cells and inhibit JNK-related apoptosis. ACS Nano 2009, 3:3358-68. 10.1021/nn900912n, 19839607.
55. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, Choi I. Vitamin D3 Up-Regulated Protein 1 Mediates Oxidative Stress Via Suppressing the Thioredoxin Function. Immunol 2000, 164:6287-6295.
56. Kalishwaralal K, Deepak V, Pandian SRK, Gurunathan S. Biological synthesis of gold nanocubes using Bacillus licheniformis. Bioresour Technol 2009, 100:5356-5358. 10.1016/j.biortech.2009.05.051, 19574037.
57. Kalishwaralal K, Gopalram S, Vaidyanathan R, Deepak V, Pandian SRK, Gurunathan S. Optimization of α-amylase production for the green synthesis of gold nanoparticles. Colloid Surf B 2010, 77:174-80.
58. Kalimuthu K, SureshBabu R, Venkataraman D, Bilal M, Gurunathan S. Biosynthesis of silver nanocrystals by Bacillus licheniformis. Colloid Surf B 2008, 65:150-153.
59. Kalishwaralal K, Deepak V, Ramkumarpandian S, Nellaiah H, Sangiliyandi G. Extracellular biosynthesis of silver nanoparticles by the culture supernatant of Bacillus licheniformis. Mater Lett 2008, 62:4411-4413.
60. Marquis BJ, Love SA, Braun KL, Haynes CL. Analytical methods to assess nanoparticle toxicity. Analyst 2009, 134:425-439. 10.1039/b818082b, 19238274.
61. Natelson S, Lugovoy J K, Pincus JB. Micro estimation of citric acid; A new colorimetric reaction for Pentabromoacetone. J Biol Chem 1948, 170(597):745-750.
62. Cury-Boaventura MF, Curi R. Regulation of reactive oxygen species (ROS) production by C18 fatty acids in Jurkat and Raji cells. Clin Sci 2005, 108:245-25. 10.1042/CS20040281, 15563273.
63. Baynes JW. Role of oxidative stress in development of complications in diabetics. Diabetes 1991, 40:405-412. 10.2337/diabetes.40.4.405, 2010041.
64. Kono Y. Generation of superoxide radical during auto-oxidation of dihydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 1978, 186:189-195. 10.1016/0003-9861(78)90479-4, 24422.
65. Seldak J, Lindsay RH. Estimation of total, protein bound and non-protein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968, 25:192-205. 10.1016/0003-2697(68)90092-4, 4973948.
66. Takahara S, Hamilton HB, Neel JV, Kobara TY, Ogura Y, Nishimura ET. Hypocatalasemia: a new genetic carrier state. J Clin Invest 1960, 39:610-619. 10.1172/JCI104075, 293346, 13836629.
67. Rotruck JT, Pope A, Ganther HE, Swanson AB. Selenium biochemical roles as a component of glutathione peroxidase. Science 1973, 179:588-590. 10.1126/science.179.4073.588, 4686466.
68. Beuge JA, Aust SV. Microsomal lipid peroxidation. Methods. Enzymol 1978, 52:302-310.